PSP Research’s Maze Therapeutics MAZE Stock Holding History

PSP Research’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,672	Closed	-$525K	–	105
2025 Q4	$525K	Buy	+12,672	New	+$436K	0.46%	55

Other funds holding MAZE

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PSP Research's MAZE Position: Q1 2026 in Review

PSP Research sold out of Maze Therapeutics (MAZE) in Q1 2026, closing a stake of 12,672 shares — an estimated $525K sold.

PSP Research first reported a position in MAZE in Q4 2025 and held it in 1 quarter. The position peaked at $525K in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

PSP Research reported no remaining Maze Therapeutics position as of Q1 2026 after selling out during the quarter.
PSP Research sold 12,672 Maze Therapeutics shares in Q1 2026, an estimated $525K.
PSP Research first reported a position in Maze Therapeutics in Q4 2025 and held it in 1 quarter.
PSP Research's Maze Therapeutics position peaked at $525K in Q4 2025.
165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on PSP Research's 13F filing for Q1 2026, filed 17 Apr 2026.